AstraZeneca Stock Tumbles After Q4 Performance – Here’s Why



AstraZeneca Plc (NASDAQ:AZNreported fourth-quarter 2023 sales of $12.02 billion, up 7% Y/Y (+8% at constant currency), slightly below the consensus of $12.09 billion, fueled by strong global demand growth for cancer drugs.

Excluding COVID-19 medicines, fourth quarter 2023 revenue increased by 16% to $12.04 billion.

The company reported a core EPS of $1.45, up 5% (+7% on constant currency), with earnings per ADS reached $0.72, missing the consensus of $0.79.

Also Read: AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study.

Citing some analysts, the Wall Street Journal noted that AstraZeneca shares …

Full story available on


Leave a Reply

Your email address will not be published. Required fields are marked *